BioCentury | Nov 16, 2016
Financial News

Glycomine raises $12M in series A round

Rare disease company Glycomine Inc. (San Francisco, Calif.) raised $12 million in a series A round led by Sanderling Ventures and Chiesi Ventures. The company's preclinical lead program is substrate replacement therapy Lipo-M1P to treat...
BioCentury | Aug 6, 2012
Company News

Lipomics, Metabolon deal

...Metabolon acquired Lipomics for an undisclosed sum. Lipomics provides metabolite profiling, biomarker discovery and metabolism consultation...
...is a suite of panels that analyze metabolic, cardiovascular and inflammatory pathways. Metabolon said the Lipomics...
...disease and cancer. Steven Watkins, founder of Lipomics, will become chief technology officer at Metabolon. Lipomics Technologies Inc....
BioCentury | Sep 22, 2008
Company News

Lipomics, Tethys Bioscience deal

...Tethys acquired metabolic profiling company Lipomics for an undisclosed amount. Tethys said Lipomics' metabolite profiling technology...
...West Sacramento headquarters. Steven Watkins, president and CSO of Lipomics, will become CTO at Tethys. Lipomics Technologies Inc....
BioCentury | Jan 28, 2008
Company News

Clinical Data management update

...Business: Supply/Service, Pharmacogenetics Hired: Meeta Patnaik as SVP of predictive diagnostics development, formerly CMO of Lipomics Technologies Inc. WIR...
BioCentury | Jul 23, 2007
Company News

Lipomics, University of California deal

...study the pathogenesis of non-insulin dependent diabetes mellitus, obesity and other disorders of insulin resistance. Lipomics...
...exclusive rights to develop diagnostic applications. Financial terms of the two-year deal were not disclosed. Lipomics Technologies Inc....
BioCentury | May 28, 2007
Company News

Lipomics, Duke University deal

...such as schizophrenia and depression, and response to statins and other drugs in cardiovascular patients. Lipomics...
...has an option to license the biomarkers for diagnostic use. Financial terms were not disclosed. Lipomics Technologies Inc....
BioCentury | Mar 5, 2007
Company News

Lipomics, University of California deal

...biomarkers associated with metabolic diseases. All IP discovered under the deal will be jointly owned. Lipomics...
...to use the biomarkers for diagnostics, and the university would be eligible for a royalty. Lipomics Technologies Inc....
BioCentury | Feb 19, 2007
Company News

Agilent, Lipomics deal

...lipid metabolism. The partners will combine Agilent’s Agilent 2100 Bioanalyzer and other analytical platforms with Lipomics’...
...and validation technologies. Further terms were not disclosed. Agilent Technologies Inc. (A), Santa Clara, Calif. Lipomics Technologies Inc....
BioCentury | Feb 19, 2007
Company News

Isis, Lipomics deal

...lipid metabolites during preclinical and clinical testing of ISIS’s preclinical compounds to treat metabolic disease. Lipomics...
...data to develop diagnostics. Financial terms were not disclosed. Isis Pharmaceuticals Inc. (ISIS), Carlsbad, Calif. Lipomics Technologies Inc....
BioCentury | Sep 11, 2006
Company News

Lipomics management update

Lipomics Technologies Inc. , West Sacramento, Calif. Business: Supply/Service Hired: Meeta Patnaik as CMO, formerly SVP, CSO and CTO at Pathway Diagnostics Corp. WIR Staff...
Items per page:
1 - 10 of 27
BioCentury | Nov 16, 2016
Financial News

Glycomine raises $12M in series A round

Rare disease company Glycomine Inc. (San Francisco, Calif.) raised $12 million in a series A round led by Sanderling Ventures and Chiesi Ventures. The company's preclinical lead program is substrate replacement therapy Lipo-M1P to treat...
BioCentury | Aug 6, 2012
Company News

Lipomics, Metabolon deal

...Metabolon acquired Lipomics for an undisclosed sum. Lipomics provides metabolite profiling, biomarker discovery and metabolism consultation...
...is a suite of panels that analyze metabolic, cardiovascular and inflammatory pathways. Metabolon said the Lipomics...
...disease and cancer. Steven Watkins, founder of Lipomics, will become chief technology officer at Metabolon. Lipomics Technologies Inc....
BioCentury | Sep 22, 2008
Company News

Lipomics, Tethys Bioscience deal

...Tethys acquired metabolic profiling company Lipomics for an undisclosed amount. Tethys said Lipomics' metabolite profiling technology...
...West Sacramento headquarters. Steven Watkins, president and CSO of Lipomics, will become CTO at Tethys. Lipomics Technologies Inc....
BioCentury | Jan 28, 2008
Company News

Clinical Data management update

...Business: Supply/Service, Pharmacogenetics Hired: Meeta Patnaik as SVP of predictive diagnostics development, formerly CMO of Lipomics Technologies Inc. WIR...
BioCentury | Jul 23, 2007
Company News

Lipomics, University of California deal

...study the pathogenesis of non-insulin dependent diabetes mellitus, obesity and other disorders of insulin resistance. Lipomics...
...exclusive rights to develop diagnostic applications. Financial terms of the two-year deal were not disclosed. Lipomics Technologies Inc....
BioCentury | May 28, 2007
Company News

Lipomics, Duke University deal

...such as schizophrenia and depression, and response to statins and other drugs in cardiovascular patients. Lipomics...
...has an option to license the biomarkers for diagnostic use. Financial terms were not disclosed. Lipomics Technologies Inc....
BioCentury | Mar 5, 2007
Company News

Lipomics, University of California deal

...biomarkers associated with metabolic diseases. All IP discovered under the deal will be jointly owned. Lipomics...
...to use the biomarkers for diagnostics, and the university would be eligible for a royalty. Lipomics Technologies Inc....
BioCentury | Feb 19, 2007
Company News

Agilent, Lipomics deal

...lipid metabolism. The partners will combine Agilent’s Agilent 2100 Bioanalyzer and other analytical platforms with Lipomics’...
...and validation technologies. Further terms were not disclosed. Agilent Technologies Inc. (A), Santa Clara, Calif. Lipomics Technologies Inc....
BioCentury | Feb 19, 2007
Company News

Isis, Lipomics deal

...lipid metabolites during preclinical and clinical testing of ISIS’s preclinical compounds to treat metabolic disease. Lipomics...
...data to develop diagnostics. Financial terms were not disclosed. Isis Pharmaceuticals Inc. (ISIS), Carlsbad, Calif. Lipomics Technologies Inc....
BioCentury | Sep 11, 2006
Company News

Lipomics management update

Lipomics Technologies Inc. , West Sacramento, Calif. Business: Supply/Service Hired: Meeta Patnaik as CMO, formerly SVP, CSO and CTO at Pathway Diagnostics Corp. WIR Staff...
Items per page:
1 - 10 of 27